Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Selective estrogen receptor modulators and postmenopausal health.

E B Roe1, K M Chiu, C D Arnaud

  • 1University of California, Department of Medicine, San Francisco, USA.

Advances in Internal Medicine
|January 15, 2000
PubMed
Summary

Selective estrogen receptor modulators (SERMs) offer benefits for postmenopausal women, including bone protection and potential cardiovascular advantages. Further research is needed to confirm long-term safety and efficacy for various conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Right mini-parasternotomy may be a good minimally invasive alternative to full sternotomy for cardiac valve operations-a propensity-adjusted analysis.

The Journal of cardiovascular surgery·2014
Same author

Simple configuration to generate short bursts of picosecond optical pulses.

Applied optics·2010
Same author

Bullet embolisation from the right subclavian vein to the right ventricle: a case report.

Emergency medicine journal : EMJ·2009
Same author

Bone density and fragility fractures in patients with developmental disabilities.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2008
Same author

Rupture of renal artery aneurysm due to Salmonella infection in a patient with systemic lupus erythematosus.

Lupus·2008
Same author

Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2003

Area of Science:

  • Endocrinology and Pharmacology
  • Women's Health
  • Oncology

Background:

  • Selective Estrogen Receptor Modulators (SERMs) are a class of drugs with mixed estrogen agonist/antagonist properties.
  • These agents show promise for managing postmenopausal changes, particularly osteoporosis and cardiovascular health.
  • Concerns regarding hormone replacement therapy (HRT) side effects drive interest in SERMs.

Purpose of the Study:

  • To review the efficacy and safety of SERMs, focusing on Raloxifene and Tamoxifen.
  • To evaluate the potential of SERMs in preventing postmenopausal bone loss, fractures, and cardiovascular events.
  • To explore the role of SERMs in primary breast cancer prevention.

Main Methods:

  • Review of existing literature on SERM clinical trials and pharmacological profiles.

Related Experiment Videos

  • Analysis of data regarding effects on bone mineral density, lipoprotein levels, and uterine tissue.
  • Evaluation of evidence for breast cancer risk reduction and prevention.

    • Main Results:

    • Raloxifene effectively prevents bone loss and may reduce fractures in postmenopausal osteoporosis, with cardioprotective lipoprotein changes and no uterine stimulation.
    • Tamoxifen is effective for primary breast cancer prevention in high-risk women, offering bone and lipoprotein benefits.
    • Newer SERMs are in development with potentially enhanced tissue-specific effects.

    Conclusions:

    • Raloxifene is a viable alternative to HRT for postmenopausal bone loss, especially for women concerned about breast cancer or bleeding risks.
    • Further long-term studies are required to ascertain Raloxifene's impact on fractures, cardiac events, dementia, and primary breast cancer prevention.
    • The future likely involves a selection of tailored SERMs based on individual patient profiles and risk factors.